RecruitingPhase 2NCT06601465

COgnitioN With VERiciGuat Evaluation in Heart Failure

CONVERGE-HF: COgnitioN With VERiciGuat Evaluation in Heart Failure

Sponsor

University of Alberta

Enrollment

120 participants

Start Date

Jun 3, 2025

Study Type

INTERVENTIONAL

Conditions

Heart Failure Cognitive Impairment

Summary

CONVERGE-HF is a 4-center pilot phase IIb randomized control trial in ambulatory patients with chronic heart failure (≥ 6 months) and mild-to-moderate cognitive impairment.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Adult patients
Established chronic heart failure (≥ 6 months)
Mild-to-moderate cognitive impairment (as per the diagnosis of cognitive impairment or a Montreal Cognitive Assessment (MoCA) score 10-25).

Exclusion Criteria6

Patients who have contraindications for sGC stimulator and vericiguat therapy (i.e. use of long-acting nitrates, other soluble guanylate cyclase stimulators (e.g., riociguat), or phosphodiesterase type 5 (PDE-5), pregnancy or breast-feeding)
Unable to undergo CMR imaging or brain MRI.
CMR exclusions: incompatible implantable cardiac device (ICD or CRT), uncontrolled atrial fibrillation or recurrent ventricular arrhythmias).
General medical conditions: uncontrolled thyroid disorders, hepatic failure, or myocardial revascularization procedures \[coronary angioplasty and/or surgical revascularization in the previous 3 months\], cancer/malignancy, or with severe dementia).
Patients with allergies to the study products.
Patients currently hospitalized.